**Specifications Table**TableSubject area*Medicine*More specific subject area*Cardiology*Type of data*Table and figure*How data was acquired*Systematic review with Review Manager 5.2*Data format*Analyzed*Experimental factors*None*Experimental features*None*Data source location*NA*Data accessibility*Data are within this article*

**Value of the data**•High quality data cover eight randomized clinical trials.•Provide EBM data concerning triple antiplatelet therapy in type 2 diabetes patients.•Data is helpful for the clinical therapy of patients with type 2 diabetes and coronary artery disease.•Researchers or physicians can use our data for analysis or clinical report.

1. Data {#s0005}
=======

Dual antiplatelet therapy consisting of aspirin and clopidogrel is a cornerstone of management for coronary artery disease (CAD) patients, especially for those who have received stents implantation. Previous studies have found that addition of cilostazol was an effective and relatively safe strategy in preventing major adverse cardiac events (MACEs) in type 2 diabetes mellitus (T2DM) patients. The value of triple antiplatelet therapy had not been well proved. Therefore, this meta-analysis was conducted to systematically evaluate the efficiency and safety of this strategy in the treatment of T2DM patients.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Design, materials and methods {#s0015}
----------------------------------

Relevant studies were identified from PubMed, Cochrane Library, Wanfang Database, Science Direct and Embase. The key words included cilostazol, stent, percutaneous coronary intervention and diabetes. A total of 1403 relevant publications were found in the initial internet retrieval. One of the articles [@bib1] was excluded because it was a sub-study of another one [@bib2] and was conducted by the same research group. Finally, eight randomized controlled trials (RCTs) [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9] met the inclusion criteria and were enrolled ([Fig. 1](#f0005){ref-type="fig"}). The dosage of cilostazol was 200 mg per day for 6 months. Data including the first author׳s surname, publication year, region, case number, gender, age, demographic data, target population, treatment protocol, follow-up period, efficacy outcomes and safety outcomes were extracted ([Table 1](#t0005){ref-type="table"}).The primary efficacy outcome was MACEs which was defined as a composite of cardiac death, myocardial infarction (MI), stroke, target vessel revascularization (TVR), target lesion revascularization (TLR), or stent thrombosis.Fig. 1Flow diagram of the literature search process of this meta-analysis.Fig. 1Table 1Main characteristics of all studies included in meta-analysis.Table 1**StudyCountryNumber Dual / TripleMean age (yrs) Dual / TripleMale (%) Dual / TripleHypertension (%) Dual / TripleHypercholesterolemia (%) Dual / TripleCurrent smoker (%) Dual / TripleMultivessel disease (%) Dual / TripleFollow-up (m) Dual / Triple**Gao [@bib9]China156/16264.3/65.255.8/54.943.6/45.146.2/53.148.7/50.659.5/48.21Lee [@bib8]Korea84/9262.1/60.971.5/70.064.7/58.445.0/42.430.1/30.437.3/34.812Li 2010 [@bib6]China30/30NANANANANANA9Shen [@bib7]China80/8069.6/67.975/73.862.5/68.838.8/36.246.2/43.8NA12Han [@bib2]China122/14159.6/59.577.0/71.672.1/70.955.7/53.943.4/44.772.1/80.112Lee [@bib5]Korea200/20060.7/61.057.0/59.059.5/59.528.5/30.531.5/24.862.5/65.59Lu [@bib4]China79/7861.0/61.0NANANANANA6Lee [@bib3]Korea81/8561.2/60.963.6/64.855.2/54.828.4/30.037.2/37.659.6/66.89[^1]

2.2. Meta-analysis {#s0020}
------------------

All statistical tests were performed with Review Manager 5.2 from the Cochrane Collaboration. Odds ratio (OR) with 95% confidence interval (CI) was used. The pooled OR was performed for dominant model. P value ≤0.10 was considered to be significant for statistical heterogeneity. Random-effect model was chosen in this study to reduce the potential bias. According to the funnel plot ([Suppl. 1](#s0040){ref-type="sec"}) and risk of bias graph ([Suppl. 2](#s0040){ref-type="sec"}), the reporting biases of this study was acceptable.

The data here showed that the risk of TVR (5.2% vs. 10.5%, OR 0.46 \[0.30, 0.71\], *P* = 0.0004, \[[Fig. 2](#f0010){ref-type="fig"}\]), TLR (3.4% vs. 7.8%, OR 0.42 \[0.22, 0.81\], *P* = 0.009, \[[Fig. 3](#f0015){ref-type="fig"}\]) and MACEs (5.9% vs. 12.1%, OR 0.44 \[0.29, 0.68\], *P* = 0.0002, \[[Fig. 4](#f0020){ref-type="fig"}\]) in Triple group were lower than that of Dual group. There was no significant difference in the comparison of stent thrombosis and bleeding events between the two groups (4.1% vs. 3.5%, OR 1.16 \[0.69, 1.95\], *P* = 0.57, \[[Fig. 5](#f0025){ref-type="fig"}\]).Fig. 2Forest plot of the risk of TVR. The risk of TVR in Triple group was lower than that of Dual group during a follow-up of 12 months after stents implantation.Fig. 2Fig. 3Forest plot of the risk of TLR. Compared to Dual group, the risk of TLR in Triple group was reduced significantly.Fig. 3Fig. 4Forest plot of the risk of MACEs. Compared to Dual group, the risk of MACEs was reduced significantly in Triple group after stents implantation.Fig. 4Fig. 5Forest plot of the risk of bleeding events. The risk of bleeding events were similar in Dual and Triple group during a follow-up of 12 months after stents implantation.Fig. 5
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[^1]: NA: not available.
